Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
A 50-year-old woman who had previously undergone right hemicolectomy and chemotherapy for colorectal cancer was hospitalized with respiratory failure. Chest computed tomography showed reticulonodular opacities and enlarged lymph nodes. A transbronchial biopsy revealed adenocarcinoma with epidermal growth factor receptor (EGFR) mutations T790M and L861Q. Treatment with the EGFR-tyrosine kinase inhibitor (TKI) osimertinib was started, and she achieved a partial response. We diagnosed her with metastatic lung tumors from colorectal cancer based on additional immunohistochemical staining and the EGFR mutation status (L861Q) of the specimens. Although cases with EGFR mutations have been rarely reported, an EGFR-TKI can be an effective treatment option for colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“EGFR is frequently overexpressed but is rarely mutated in CRC, and tyrosine kinase inhibitors (TKIs) targeting mutant-selective EGFR are not effective as single agents for mCRC treatment [28].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 1×
“EGFR-tyrosine kinase inhibitors (TKIs) are associated with remarkable tumor responses compared with standard cytotoxic chemotherapy in patients with NSCLC harboring EGFR mutations (4-6).”
BackgroundCOSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Midha, A., Dearden, S. P., & McCormack, R. (2015) · Europe PMC (PubMed Central) · Cited by 1,074
ErbB Receptors: Directing Key Signaling Networks Throughout Life
Holbro, T., & Hynes, N. E. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 640 · cited 1×
“Epidermal growth factor receptor (EGFR) is a type I receptor tyrosine kinase that regulates the cell proliferation, differentiation, division, survival, and cancer development (1, 2).”
BackgroundImpact of EGFR expression on colorectal cancer patient prognosis and survival
Spano, J.-P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., Attar, A., Benichou, J., Martin, A., Morere, J.-F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi006 · Cited by 462 · cited 1×
“Epidermal growth factor receptor (EGFR) is a type I receptor tyrosine kinase that regulates the cell proliferation, differentiation, division, survival, and cancer development (1, 2).”
BackgroundCho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358 · cited 5×
“Further studies will be required to clarify whether or not EGFR-TKIs are effective in colorectal cancer with EGFR mutations other than primary lung cancer.”
MethodInfluentialSomatic Mutations of EGFR in Colorectal Cancers and Glioblastomas
Barber, T. D., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512724 · Cited by 315 · cited 1×
“While approximately 50% of colorectal cancers have amplification of the EGFR gene (9), mutations of the EGFR gene are rare (2-3%) (10).”
Background
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“…CRC); strategies targeting EGFR are central to the treatment of liver metastatic disease (Figure 2 EGFR is frequently overexpressed but is rarely mutated in CRC, and tyrosine kinase inhibitors (TKIs) targeting mutant-selective EGFR are not effective as single agents for mCRC treatment [28].”
BackgroundAmrutha Krishnan, K., Valavi, S. G., & Joy, A. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206275566231206094645 · Cited by 9
Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
Buzard, B., Douglass, L., Gustafson, B., Buckley, J. L., Roth, M., Kujtan, L. A., & Bansal, D. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i10.1829 · Cited by 9
Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis
Zhang, K., Ayala, A., Norambuena‐Soto, I., Agnihotri, V., Shu, T., Nenninger, C. H., Wang, Y., Echevarria, B., Aboagye, J., Huang, K. T., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf813 · Cited by 6
“10 14 Patients with concurrent hypertension and osimertinib treatment would be at a particularly increased risk of cardiotoxicity.”
Metastatic colorectal adenocarcinoma with APC and EGFR L858R co-mutations: a case report
Cavalheiro, V. J., Filho, D. S. R. S., de Oliveira, G. M., da Fonseca, M. D. R. N., Travessini, G., Soares, I. C., de Castro, G., Sabbaga, J., Mak, M. P., & Hoff, P. M. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf421 · Cited by 1
Metadata
- Authors
- Yanagisawa, A., Kinehara, Y., Kijima, R., Tanaka, M., Ninomiya, R., Jokoji, R., & Tachibana, I.
- Affiliations
- Nippon Life Hospital (JP)
- Venue
- Internal Medicine
- Published
- 2023-03-01
- Volume
- 62
- Issue
- 5
- Pages
- 769-773
- ISSN
- 0918-2918 (ISSN-L)
- 1349-7235
- PMC
- PMC10037001
- OpenAlex
- W4286384836
- Cited by
- 7
- References
- 19
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 2
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- other-oa
- Locations
- Internal Medicine (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Metastasis and carcinoma case studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, lung metastasis, EGFR mutation, osimertinib, EGFR tyrosine kinase inhibitors, T790M, L861Q, adenocarcinoma, immunohistochemistry, partial response, hemicolectomy
- MeSH terms
- Acrylamides, Aniline Compounds, Female, Humans, Indoles, Lung Neoplasms, Middle Aged, Mutation, Pyrimidines, Colorectal Neoplasms, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib. https://app.cochat.ai/papers/10.2169/internalmedicine.0002-22
- The paper
- Yanagisawa, A., Kinehara, Y., Kijima, R., Tanaka, M., Ninomiya, R., Jokoji, R., & Tachibana, I. (2023). Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib. Internal Medicine. https://doi.org/10.2169/internalmedicine.0002-22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.